Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection
An Open Label Safety Study to Evaluate the Safety of Tipranavir Plus Ritonavir When Used in Combination With Other Agents for the Treatment of Patients With HIV Infection Who Have Failed and/or Are Intolerant to Combination Antiretroviral Therapy and Have Limited Treatment Options
Sponsor: Boehringer Ingelheim
Listed as NCT00062660, this observational or N/A phase trial focuses on HIV Infections and remains ongoing. Sponsored by Boehringer Ingelheim, it has been updated 7 times since 2003, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Approved For Marketing
-
Sep 2024 — Sep 2025 [monthly]
Approved For Marketing
-
Jul 2024 — Sep 2024 [monthly]
Approved For Marketing
-
Jan 2021 — Jul 2024 [monthly]
Approved For Marketing
-
Jun 2018 — Jan 2021 [monthly]
Approved For Marketing
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Approved For Marketing
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Approved For Marketing NA
First recorded
May 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aarhus C, Denmark, Adelaide, Australia, Aix-en-Provence, France, Antwerp, Belgium, Athens, Greece, Atlanta, United States, Basel, Switzerland, Beckenham, United Kingdom, Bedford Park, Australia, Bern, Switzerland and 99 more location s